Skip to main content
Top
Published in: Critical Care 2/2003

Open Access 01-04-2004 | Research

Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]

Authors: Gary T Kinasewitz, S Betty Yan, Bruce Basson, Philip Comp, James A Russell, Alain Cariou, Suzane L Um, Barbara Utterback, Pierre-Francois Laterre, Jean-François Dhainaut, for the PROWESS Sepsis Study Group

Published in: Critical Care | Issue 2/2003

Login to get access

Abstract

Introduction

PROWESS (Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis) was a phase III, randomized, double blind, placebo controlled, multicenter trial conducted in patients with severe sepsis from 164 medical centers. Here we report data collected at study entry for 1690 patients and over the following 7 days for the 840 patients who received placebo (in addition to usual standard of care).

Methods

Nineteen biomarkers of coagulation activation, anticoagulation, fibrinolysis, endothelial injury, and inflammation were analyzed to determine the relationships between baseline values and their change over time, with 28-day survival, and type of infecting causative micro-organism.

Results

Levels of 13 of the 19 biomarkers at baseline correlated with Acute Physiology and Chronic Health Evaluation II scores, and nearly all patients exhibited coagulopathy, endothelial injury, and inflammation at baseline. At study entry, elevated D-dimer, thrombin–antithrombin complexes, IL-6, and prolonged prothrombin time were present in 99.7%, 95.5%, 98.5%, and 93.4% of patients, respectively. Markers of endothelial injury (soluble thrombomodulin) and deficient protein C, protein S, and antithrombin were apparent in 72%, 87.6%, 77.8%, and 81.7%, respectively. Impaired fibrinolysis (elevated plasminogen activator inhibitor-1) was observed in 44% of patients. During the first 7 days, increased prothrombin time (which is readily measurable in most clinical settings) was highly evident among patients who were not alive at 28 days.

Conclusion

Abnormalities in biomarkers of inflammation and coagulation were related to disease severity and mortality outcome in patients with severe sepsis. Coagulopathy and inflammation were universal host responses to infection in patients with severe sepsis, which were similar across causative micro-organism groups.
Literature
1.
go back to reference Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.Crit Care Med 2001, 29:1303–1310.CrossRef Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.Crit Care Med 2001, 29:1303–1310.CrossRef
2.
go back to reference Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.Chest 1992, 101:1644–1655.CrossRef Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.Chest 1992, 101:1644–1655.CrossRef
3.
go back to reference Corrigan JJ, Ray WL, May N: Changes in the blood coagulation system associated with septicemia.N Engl J Med 1968, 279:851–856.CrossRef Corrigan JJ, Ray WL, May N: Changes in the blood coagulation system associated with septicemia.N Engl J Med 1968, 279:851–856.CrossRef
4.
go back to reference ten Cate H, Timmerman JJ, Levi M: The pathophysiology of disseminated intravascular coagulation.Thromb Haemost 1999, 82:713–717. ten Cate H, Timmerman JJ, Levi M: The pathophysiology of disseminated intravascular coagulation.Thromb Haemost 1999, 82:713–717.
5.
go back to reference Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, Mercier JC, Offenstadt G, Regnier B: Incidence, risk factors and outcome of severe sepsis and septic shock in adults.JAMA 1995, 274:968–974.CrossRef Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, Mercier JC, Offenstadt G, Regnier B: Incidence, risk factors and outcome of severe sepsis and septic shock in adults.JAMA 1995, 274:968–974.CrossRef
6.
go back to reference Bernard GR, Vincent JL, Laterre PF, Larosa SP, Dhainaut JF, Lopez-Rodriguez AL, Steingrub JS, Garber GE, Helterbrand JD, Ely EW: Efficacy and safety of recombinant human activated protein C for treatment of patients with severe sepsis.N Engl J Med 2001, 344:699–709.CrossRef Bernard GR, Vincent JL, Laterre PF, Larosa SP, Dhainaut JF, Lopez-Rodriguez AL, Steingrub JS, Garber GE, Helterbrand JD, Ely EW: Efficacy and safety of recombinant human activated protein C for treatment of patients with severe sepsis.N Engl J Med 2001, 344:699–709.CrossRef
7.
go back to reference Fulton R, McDade R, Smith P, Kieker L, Kettman J: Advanced multiplexed analysis with the FlowMetrix system.Clin Chem 1997, 43:1749–1756. Fulton R, McDade R, Smith P, Kieker L, Kettman J: Advanced multiplexed analysis with the FlowMetrix system.Clin Chem 1997, 43:1749–1756.
8.
go back to reference Webster NR: Inflammation and the coagulation system.Br J Anaesth 2002, 89:216–220.CrossRef Webster NR: Inflammation and the coagulation system.Br J Anaesth 2002, 89:216–220.CrossRef
9.
go back to reference Boffa MB, Hamill JD, Bastajian N, Dillon R, Nesheim ME, Koschinsky ML: A role for CCAAT/Enhancer-binding protein in hepatic expression of thrombin-activable fibrinolysis inhibitor.J Biol Chem 2002, 277:25329–25336.CrossRef Boffa MB, Hamill JD, Bastajian N, Dillon R, Nesheim ME, Koschinsky ML: A role for CCAAT/Enhancer-binding protein in hepatic expression of thrombin-activable fibrinolysis inhibitor.J Biol Chem 2002, 277:25329–25336.CrossRef
10.
go back to reference van der Poll T, Lowry SF: Tumor necrosis factor in sepsis: mediator of multiple organ failure or essential part of host defense?Shock 1995, 3:1–12. van der Poll T, Lowry SF: Tumor necrosis factor in sepsis: mediator of multiple organ failure or essential part of host defense?Shock 1995, 3:1–12.
11.
go back to reference Oberholzer A, Oberholzer C, Moldawer LL: Interleukin-10: a complex role in the pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug.Crit Care Med 2002, Suppl:S58-S63.CrossRef Oberholzer A, Oberholzer C, Moldawer LL: Interleukin-10: a complex role in the pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug.Crit Care Med 2002, Suppl:S58-S63.CrossRef
12.
go back to reference Latifi SQ, O'Riordan MA, Lavine AD: Interleukin-10 controls the onset of irreversible septic shock.Infect Immun 2002, 70:4441–4446.CrossRef Latifi SQ, O'Riordan MA, Lavine AD: Interleukin-10 controls the onset of irreversible septic shock.Infect Immun 2002, 70:4441–4446.CrossRef
13.
go back to reference Lorente JA, Garcia-Frade LJ, Landin L, de Pablo R, Torrado C, Renes E, Garcia-Avello A: Time course of hemostatic abnormalities in sepsis and its relation to outcome.Chest 1993, 103:1536–1542.CrossRef Lorente JA, Garcia-Frade LJ, Landin L, de Pablo R, Torrado C, Renes E, Garcia-Avello A: Time course of hemostatic abnormalities in sepsis and its relation to outcome.Chest 1993, 103:1536–1542.CrossRef
14.
go back to reference Gando S, Nanzaki S, Sasaki S, Kenichiro A: Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock.Crit Care Med 1998, 26:2005–2009.CrossRef Gando S, Nanzaki S, Sasaki S, Kenichiro A: Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock.Crit Care Med 1998, 26:2005–2009.CrossRef
15.
go back to reference Martinez MA, Pena JM, Fernandez A, Jimenez M, Juarez S, Madero R, Vazquez JJ: Time course and prognostic significance of hemostatic changes in sepsis: relation to tumor necrosis factor-α.Crit Care Med 1999, 27:1303–1308.CrossRef Martinez MA, Pena JM, Fernandez A, Jimenez M, Juarez S, Madero R, Vazquez JJ: Time course and prognostic significance of hemostatic changes in sepsis: relation to tumor necrosis factor-α.Crit Care Med 1999, 27:1303–1308.CrossRef
16.
go back to reference Hesselvik JF, Blomback M, Brodin B, Maller R: Coagulation, fibrinolysis, and kallikrein systems in sepsis: relation to outcome.Crit Care Med 1989, 17:724–733.CrossRef Hesselvik JF, Blomback M, Brodin B, Maller R: Coagulation, fibrinolysis, and kallikrein systems in sepsis: relation to outcome.Crit Care Med 1989, 17:724–733.CrossRef
17.
go back to reference Mesters RM, Mannucci PM, Coppola R, Keller T, Ostermann H, Kienast J: Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients.Blood 1996, 88:881–886. Mesters RM, Mannucci PM, Coppola R, Keller T, Ostermann H, Kienast J: Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients.Blood 1996, 88:881–886.
18.
go back to reference Mesters RM, Helterbrand J, Utterback BG, Yan SB, Chao B, Fernandaz JA, Griffin JH, Hartman DL: Prognostic value of protein C levels in neutropenic patients at high risk of severe septic complications.Crit Care Med 2000, 28:2209–2216.CrossRef Mesters RM, Helterbrand J, Utterback BG, Yan SB, Chao B, Fernandaz JA, Griffin JH, Hartman DL: Prognostic value of protein C levels in neutropenic patients at high risk of severe septic complications.Crit Care Med 2000, 28:2209–2216.CrossRef
19.
go back to reference Taylor FB, Toh CH, Hoots WK, Wada H, Levi M: Towards definition, clinical and labortory criteria, and a scoring system for disseminated intravascular coagulation (on behalf of the scientific subcommittee on disseminated intravascular coagulation (DIC) of the international society on thrombosis and haemostasis (ISTH).Thromb Haemost 2001, 86:1327–1330. Taylor FB, Toh CH, Hoots WK, Wada H, Levi M: Towards definition, clinical and labortory criteria, and a scoring system for disseminated intravascular coagulation (on behalf of the scientific subcommittee on disseminated intravascular coagulation (DIC) of the international society on thrombosis and haemostasis (ISTH).Thromb Haemost 2001, 86:1327–1330.
Metadata
Title
Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]
Authors
Gary T Kinasewitz
S Betty Yan
Bruce Basson
Philip Comp
James A Russell
Alain Cariou
Suzane L Um
Barbara Utterback
Pierre-Francois Laterre
Jean-François Dhainaut
for the PROWESS Sepsis Study Group
Publication date
01-04-2004
Publisher
BioMed Central
Published in
Critical Care / Issue 2/2003
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc2459

Other articles of this Issue 2/2003

Critical Care 2/2003 Go to the issue